Litigation Details for ELI LILLY AND COMPANY v. NANG KUANG PHARMACEUTICAL CO., LTD. (S.D. Ind. 2014)

« Back to Dashboard

ELI LILLY AND COMPANY v. NANG KUANG PHARMACEUTICAL CO., LTD. (S.D. Ind. 2014)

Docket		Date Filed	2014-10-08
Court	District Court, S.D. Indiana	Date Terminated	2018-02-21
Cause	35:271 Patent Infringement	Assigned To	Tanya Walton Pratt
Jury Demand	Defendant	Referred To	Matthew Brookman
Patents	7,772,209
Link to Docket	External link to docket

Details for ELI LILLY AND COMPANY v. NANG KUANG PHARMACEUTICAL CO., LTD. (S.D. Ind. 2014)

Date Filed	Document No.	Description	Snippet	Link To Document
2014-10-08				External link to document

Eli Lilly v. Nang Kuang Pharmaceutical Patent Litigation: Case No. 1:14-cv-01647

Last updated: September 26, 2026

Eli Lilly sued Nang Kuang Pharmaceutical Co., Ltd. in the U.S. District Court for the District of Delaware after Nang Kuang filed an abbreviated new drug application seeking approval for a generic version of Alimta, Lilly’s pemetrexed product. The case was an ANDA Paragraph IV dispute involving Lilly’s pemetrexed patent estate. It ended without a public merits decision, published claim-construction ruling, or reported trial verdict. The parties resolved the matter through a confidential settlement and the action was dismissed.

What drug and patent rights were involved in Eli Lilly v. Nang Kuang?

The dispute concerned pemetrexed, an antifolate chemotherapy drug marketed by Lilly as Alimta.

Item	Case information
Plaintiff	Eli Lilly and Company
Defendant	Nang Kuang Pharmaceutical Co., Ltd.
Court	U.S. District Court for the District of Delaware
Civil action	No. 1:14-cv-01647
Filing period	2014
Product	Generic pemetrexed for injection
Regulatory pathway	Abbreviated New Drug Application
Certification	Paragraph IV patent certification
Primary commercial product	Alimta
Litigation outcome	Settlement and dismissal
Public merits ruling	None reported
Settlement terms	Not publicly disclosed

The litigation formed part of Lilly’s broader effort to protect Alimta against generic pemetrexed applications. The principal Orange Book patent associated with the Alimta litigation at that time was U.S. Patent No. 7,772,209, which covered pemetrexed-related pharmaceutical subject matter and had an Orange Book-listed expiration in 2021, subject to applicable patent-term adjustments or pediatric exclusivity.[1][2]

The case should be distinguished from later litigation involving Lilly’s vitamin pretreatment patent, U.S. Patent No. 9,340,614. That patent was issued after the Nang Kuang action began and was not the central patent at issue in the 2014 complaint.

Why did Lilly sue Nang Kuang?

Lilly sued because Nang Kuang’s ANDA filing was treated as an artificial act of patent infringement under the Hatch-Waxman Act. A Paragraph IV certification states that a listed patent is invalid, unenforceable, or will not be infringed by the proposed generic product.

Under 35 U.S.C. § 271(e)(2), submitting an ANDA with a Paragraph IV certification creates a statutory cause of action before the generic product reaches the market. Lilly therefore did not need to wait for Nang Kuang to sell pemetrexed in the United States.

The complaint sought the standard remedies in an ANDA case:

1. A declaration that the asserted patent was valid, enforceable, and infringed.
2. An order preventing FDA approval of the ANDA until patent expiration.
3. A 30-month stay of FDA approval under 21 U.S.C. § 355(j)(5)(B)(iii).
4. Attorneys’ fees and other relief available under the Patent Act.

The case was regulatory litigation as much as commercial patent litigation. The primary economic objective was to delay approval of Nang Kuang’s generic product until Lilly’s relevant patent protection expired or until the parties reached a negotiated launch arrangement.

What patents protected Alimta in the Nang Kuang case?

The Alimta patent estate included composition, formulation, manufacturing, and method-of-use rights. The patents asserted against individual ANDA applicants varied by product, filing date, and proposed labeling.

U.S. Patent No. 7,772,209

The ’209 patent was among Lilly’s important Alimta patents during the period. It was directed to pemetrexed-related pharmaceutical subject matter and was listed in connection with Alimta. Public patent records identify Eli Lilly as the assignee.[2]

Its commercial value came from the relationship between the patented subject matter and the proposed generic pemetrexed product. If the ANDA product fell within the patent claims, FDA approval could be delayed until the patent’s enforceable term ended.

Earlier Alimta patents

Lilly’s broader Alimta portfolio also included earlier patents covering pemetrexed compounds and therapeutic uses. Several of those patents had expired or were approaching expiration by the time the Nang Kuang case was filed. Their historical importance was substantial, but their remaining blocking value in 2014 depended on the particular patent, claim scope, and Orange Book listing.

Later vitamin-regimen patent

U.S. Patent No. 9,340,614 covered a vitamin pretreatment regimen used with pemetrexed. It became important in later generic litigation but was not the principal patent basis for a 2014 complaint because it had not yet issued.[3]

When did Alimta lose exclusivity?

Alimta’s regulatory and patent exclusivity did not end on a single date.

Protection type	Relevant timing
New chemical entity exclusivity	Expired before the Nang Kuang lawsuit
Earlier composition and use patents	Expired at different times before or around the litigation
U.S. Patent No. 7,772,209	Listed expiration generally reported in 2021
Pediatric exclusivity	Could extend certain regulatory protections by six months
Later vitamin-regimen patent	Extended potential method-of-use protection into the late 2020s

The 30-month stay associated with the Nang Kuang Paragraph IV litigation was not itself a patent term. It was an FDA approval stay triggered by Lilly’s timely patent suit. The stay prevented FDA approval during the statutory period unless the court issued an earlier decision or another statutory event ended the stay.[1]

The precise commercial launch date available to Nang Kuang was governed by the confidential settlement, not by the public docket alone.

What was the litigation timeline?

Date or period	Event
2014	Nang Kuang submitted an ANDA for generic pemetrexed and provided Lilly with a Paragraph IV notice
2014	Lilly filed Civil Action No. 1:14-cv-01647 in Delaware
2014-2015	The parties proceeded under the Hatch-Waxman framework
Subsequent period	The parties reached a confidential resolution
After settlement	The action was dismissed without a public trial judgment

The public docket does not show a reported final judgment declaring the asserted patent invalid or not infringed. It also does not establish a litigated claim-construction position for either party.

Did Nang Kuang file a Paragraph IV challenge?

Yes. The action was an ANDA patent case, which indicates that Nang Kuang’s application included a patent certification that triggered Lilly’s right to sue under Hatch-Waxman.

A Paragraph IV challenge is not a finding that a patent is invalid. It is a legal position taken by the ANDA applicant. The applicant typically argues that the relevant patent claims are invalid, unenforceable, or not infringed by the proposed product.

Lilly’s filing triggered the statutory litigation stay. The case therefore created a regulatory barrier to immediate FDA approval even though Nang Kuang had not yet launched a commercial product.

What was the litigation outcome?

The parties settled. The case did not produce a published district court opinion resolving validity, infringement, enablement, written description, obviousness, or inequitable conduct.

The settlement terms were confidential. The public docket does not establish:

• The agreed generic launch date.
• Whether Nang Kuang received an authorized-generic arrangement.
• Whether Lilly granted a license.
• Whether the agreement included a supply arrangement.
• Whether the settlement contained restrictions beyond the disputed ANDA.
• Whether the settlement was reviewed or challenged by the Federal Trade Commission.

The absence of a merits ruling limits the value of the case as precedent. Its primary business significance was the negotiated treatment of a potential generic entrant.

Did the case involve a biosimilar?

No. Pemetrexed is a small-molecule drug, and Nang Kuang’s application proceeded under the ANDA pathway rather than the Biologics Price Competition and Innovation Act pathway.

The relevant competitive threat was a generic injectable product, not a biosimilar. The principal regulatory issues were ANDA approval, Paragraph IV certification, the 30-month stay, bioequivalence, manufacturing compliance, and patent barriers.

What formulation and manufacturing barriers affected generic entry?

Generic pemetrexed injectable products must address more than the active ingredient. The applicant must establish pharmaceutical equivalence, strength, dosage form, route of administration, stability, sterility, container closure, labeling, and manufacturing compliance.

Potential patent barriers included:

• Pemetrexed compound claims.
• Pemetrexed salt or disodium-form claims.
• Injectable formulation claims.
• Manufacturing or preparation claims.
• Method-of-use claims tied to cancer treatment.
• Vitamin pretreatment and dosing instructions.

For injectable oncology products, manufacturing capacity can also affect launch timing. FDA approval does not guarantee immediate commercial supply. The applicant must maintain compliant sterile manufacturing, validated processes, qualified suppliers, and adequate capacity.

How strong was Lilly’s patent estate?

Lilly’s estate was commercially strong during the early generic challenge period because it combined a marketed oncology product with multiple layers of intellectual-property protection. The strength varied by patent.

Estate layer	Strategic value
Core compound patents	Strongest during early product life, but largely time-limited
Formulation patents	Could block products with closely matching injectable presentations
Method-of-use patents	Could restrict labeled oncology uses or induce infringement theories
Manufacturing patents	Could affect production methods but may be avoidable through design-around
Vitamin-regimen patent	Potentially important for labeled use and later litigation

The estate’s principal weakness was timing. Several earlier patents had expired or were nearing expiration when the Nang Kuang case began. A generic applicant could also seek a noninfringement position through a different salt, formulation, manufacturing process, or label.

The settlement avoided a public test of those issues.

What generic launch risks existed for Lilly?

The principal risks were:

1. A court ruling that the asserted patent was invalid or not infringed.
2. A negotiated launch before the full listed patent term.
3. Multiple generic applicants entering after a first settlement.
4. Price erosion from competing injectable pemetrexed products.
5. Loss of practical value in method-of-use claims if generic labeling omitted or carved out protected uses.
6. Manufacturing or supply competition from injectable oncology specialists.

Alimta revenue was exposed to the standard loss-of-exclusivity pattern: initial price compression from the first generic, followed by deeper erosion as additional suppliers entered. The actual impact depended on the settlement date, FDA approvals, generic capacity, hospital contracting, and the number of competing ANDAs.

How did Nang Kuang compare with other Alimta challengers?

Nang Kuang was one of several companies pursuing generic pemetrexed opportunities. Its case did not establish a broad legal rule applicable to every challenger.

Issue	Nang Kuang	Other Alimta challengers
Product	Generic pemetrexed injection	Generic pemetrexed products
Regulatory pathway	ANDA	ANDA
Patent posture	Paragraph IV litigation	Varied by applicant
Public merits decision	None reported	Some later cases produced substantive rulings
Settlement terms	Confidential	Often confidential or partly disclosed
Biosimilar exposure	None	None

The most important later legal developments came from other defendants and later-issued Lilly patents. Those cases provided more guidance on induced infringement, labeled use, vitamin pretreatment, and alternative pemetrexed forms than the Nang Kuang docket itself.

What is the current litigation status?

The Nang Kuang action is closed. It is not an active patent trial, and there is no public injunction or final merits judgment continuing against Nang Kuang under the case number 1:14-cv-01647.

The case remains relevant for:

• Tracking Lilly’s Alimta enforcement strategy.
• Identifying the use of Hatch-Waxman litigation against injectable generic manufacturers.
• Evaluating confidential settlement patterns.
• Assessing the timing of generic entry negotiations.
• Mapping the commercial life cycle of Lilly’s pemetrexed franchise.

Key Takeaways

• Lilly sued Nang Kuang in Delaware over an ANDA for generic pemetrexed.
• The action was a Hatch-Waxman Paragraph IV case involving Alimta-related patent rights.
• U.S. Patent No. 7,772,209 was among the important Alimta patents during the period.
• The case ended through confidential settlement and dismissal.
• No reported merits decision resolved validity or infringement.
• The dispute involved a small-molecule generic, not a biosimilar.
• Public records do not disclose the agreed launch date or other material settlement terms.
• Later-issued Alimta patents, including U.S. Patent No. 9,340,614, belong to later litigation developments and should not be treated as the principal basis of this 2014 action.

FAQs

What was the drug in Eli Lilly v. Nang Kuang?

The drug was pemetrexed for injection, the generic counterpart to Lilly’s Alimta chemotherapy product.

Was Eli Lilly v. Nang Kuang a patent infringement trial?

No. The case was filed as ANDA litigation but ended in a confidential settlement before a reported trial judgment.

Did Nang Kuang invalidate Lilly’s Alimta patents?

No. The public case record does not report a judgment invalidating Lilly’s asserted Alimta patents.

Did the Nang Kuang case involve a 180-day generic exclusivity period?

The public record does not identify Nang Kuang as obtaining first-filer status or a court-awarded 180-day exclusivity period.

Can the Nang Kuang settlement be used to predict generic pemetrexed launch timing?

Only to a limited extent. The settlement resolved the dispute but did not publicly disclose the launch date, license scope, or commercial conditions.

References

1. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. U.S. Department of Health and Human Services.

2. U.S. Patent and Trademark Office. (2010). U.S. Patent No. 7,772,209, pemetrexed-related pharmaceutical compositions and methods. U.S. Department of Commerce.

3. U.S. Patent and Trademark Office. (2016). U.S. Patent No. 9,340,614, methods of administering pemetrexed with vitamin pretreatment. U.S. Department of Commerce.

4. U.S. District Court for the District of Delaware. (2014). Eli Lilly and Company v. Nang Kuang Pharmaceutical Co., Ltd., No. 1:14-cv-01647. Federal court docket.